Another synthetic TLR4 agonist, GLA-SE, upon single systematic administration, rapidly and dose-dependently increased innate and adaptive immunity in each compartment, with no apparent off-target effects, and resulted in a reduction in metastatic progression in all tumor models examined. Here, TLR4 is linked to neoplasm.